C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Neal D. Shore,Celestia S. Higano,Daniel J. George,Cora N. Sternberg,Fred Saad,Bertrand Tombal,Kurt Miller,J. Kalinovsky,XiaoLong Jiao,Krishna Tangirala,Oliver Sartor +10 more
TL;DR: In this real-world setting, combination treatments with radium-223 and abiraterone/prednisone or enzalutamide were common and were more commonly given in a layered than a concurrent fashion.
Journal ArticleDOI
Transurethral resection of the prostate and metastatic prostate cancer.
Vito Pansadoro,Cora N. Sternberg,Francesco Depaula,Alberto Florio,Diana Giannarelli,Giorgio Arcangeli +5 more
TL;DR: It appeared that TURP did not enhance the development of metastatic disease in patients who underwent radiation therapy for prostate cancer between January 1977 and June 1990 and were retrospectively analyzed.
Journal ArticleDOI
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061
Linda Cerbone,Cora N. Sternberg,Lisa Sengeløv,Mads Agerbæk,Carla M.L. van Herpen,Sandrine Marreaud,Sandra Collette,Jianping Zhang,Gedske Daugaard +8 more
TL;DR: The maximum tolerated dose (MTD) of lapatinib combined with GC in bladder cancer was 1,250 mg, which appears safe and tolerable.
Journal ArticleDOI
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.
Thomas Powles,Se Hoon Park,Eric Voog,Claudia Caserta,Begoña Perez-Valderrama,Howard Gurney,Yohann Loriot,Srikala S. Sridhar,Norihiko Tsuchiya,Cora N. Sternberg,Joaquim Bellmunt,Jeanny B. Aragon-Ching,Daniel P. Petrylak,Andy Blake-Haskins,Robert Laliberte,Jing Y. Wang,Nuno Costa,Petros Grivas +17 more
TL;DR: Long-term follow-up from the JAVELIN Bladder 100 trial continues to show prolonged OS, and standard-of-care role for avelumab as 1L maintenance in patients with advanced UC that has not progressed with 1L platinum-containing chemotherapy is supported.
Journal ArticleDOI
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer
Axel S. Merseburger,Andrea B. Apolo,Simon Chowdhury,Noah M. Hahn,Matthew D. Galsky,Matthew I. Milowsky,Daniel P. Petrylak,Thomas Powles,David I. Quinn,Jonathan E. Rosenberg,Arlene O. Siefker-Radtke,Guru Sonpavde,Cora N. Sternberg +12 more
TL;DR: The SIU (Société Internationale d’Urologie)–ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings and came to conclusions and recommendations according to the evidence published.